Recursion Pharmaceuticals (RXRX) Goodwill & Intangibles (2020 - 2026)

Recursion Pharmaceuticals' Goodwill & Intangibles history runs 7 years deep, the most recent figure standing at $454.2 million for Q1 2026.

• Quarterly Goodwill & Intangibles fell 8.03% year-over-year to $454.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $454.2 million (down 8.03% YoY) and the FY2025 annual result came in at $472.1 million, down 2.61% from the prior year.
• Goodwill & Intangibles was $454.2 million for Q1 2026 at Recursion Pharmaceuticals, down from $472.1 million in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $505.6 million in Q2 2025 and bottomed at $1.3 million in Q1 2022.
• A 5-year average of $202.3 million and a median of $90.3 million in 2024 frame the typical range for Goodwill & Intangibles.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles plunged 45.77% — and 2024, when it surged 6359.18%.
• Recursion Pharmaceuticals' Goodwill & Intangibles stood at $2.1 million in 2022, then surged by 4100.24% to $88.5 million in 2023, then jumped by 447.72% to $484.7 million in 2024, then slipped by 2.61% to $472.1 million in 2025, then dropped by 3.77% to $454.2 million in 2026.
• Business Quant data shows RXRX's Goodwill & Intangibles at $454.2 million in Q1 2026, $472.1 million in Q4 2025, and $484.4 million in Q3 2025.